This program has received an educational grant from: Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Eisai, Gilead a Kite Company, Janssen, Merck, Pfizer, Roche, Servier, Taiho Pharma, Takeda, TevaCanada Innovation

LEARNING OBJECTIVES

• Review of the unmet need in DLBCL and the place for CAR T therapy
• Highlight CAR constructs
• Present data from key landmark CAR T studies as well as CAR T pivotal trials in DLBCL
• Discuss emerging real world evidence from the use of CAR T therapies in clinical practice

WEDNESDAY Feb 12, 2020

MUHC- GLEN
8:30 - 9:30
Room D02.1312

Hôpital Maisonneuve-Rosemont-HMR
12:00 – 13:00
Room 0-80

THURSDAY Feb 13, 2020

Hôpital Sacré-Coeur
12:00 - 13:00
Room G- 4115

CHUM
17:00 - 18:00
Room D.S4.5030

Refreshments will be served.
To organize a videoconference: vspo@mcgill.ca

Problems/Questions: 514-813-4510

“CAR T and DLBCL: From clinical trials to real world clinic.”